Skip to Content

Treatment sequence should begin with Nivo+Ipi in patients with MM

Get the main clinical outcomes from the DREAMseq trial in this MEDtalk, presented by Medical Oncologist Michael B. Atkins. To determine what drugs to begin the treatment sequence in patients with RAFV600-mutant metastatic melanoma (MM), the trial compares the efficacy of the sequence of nivolumab/ipilimumab (Nivo/Ipi) followed by dabrafenib/trametinib (Dab/Tram) to the converse sequence.

Michael B. Atkins

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top